anti-CD19 mRNA CAR-T
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 31, 2023
Capstan Therapeutics to Present Preclinical Data at SITC Demonstrating Rapid Anti-Primary B Cell and Anti-Tumor Activity in Mice with Proprietary Targeted Lipid Nanoparticles Delivering an Anti-CD19 CAR mRNA Construct
(Businesswire)
- "Capstan Therapeutics, Inc...today announced it will present preclinical data showing rapid and robust anti-tumor and anti-primary B cell activity in humanized mice by tLNP administration delivering an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR), at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, California....'We have demonstrated efficient and therapeutically relevant delivery of mRNA CAR payloads to human T cells. This resulted in rapid and profound pharmacodynamic effect in two mouse models, comprising eradication of human primary B cells or Nalm6 leukemic cells, respectively."
Preclinical • Oncology
1 to 1
Of
1
Go to page
1